Literature DB >> 8887125

Elevations of serum interleukin-12 concentrations in women with severe pre-eclampsia and HELLP syndrome.

D J Dudley1, C Hunter, M D Mitchell, M W Varner, M Gately.   

Abstract

The objective is to test the hypothesis that serum IL-12 concentrations would be elevated in women with severe pre-eclampsia and HELLP syndrome. The Methods used were as follows: Serum was obtained from women admitted to our Labor and Delivery unit diagnosed with severe pre-eclampsia or HELLP syndrome and normal control patients. IL-12 concentrations in these samples were determined by the use of two different and specific enzyme-linked immunosorbent assays for the p40 subunit and the intact p75 dimer. It was found that serum IL-12 (p40 subunit) concentrations were elevated in women with both severe pre-eclampsia (p = 0.011) or HELLP syndrome (= 0.004). Similar findings were noted for these patients when matched with control patients for maternal age, gestational age, and parity. Eleven women had elevations of serum IL-12 p75 dimer, and 10 of these 11 patients had severe pre-eclampsia or HELLP syndrome. In conclusion, we found that women with severe pre-eclampsia and HELLP syndrome commonly have detectable concentrations of the IL-12 p40 monomer and were more likely than normal control women to have detectable serum IL-12 p75 dimer. While the exact role of IL-12 in hypertensive disease during pregnancy is unclear, our data support the hypothesis that the regulation of IL-12 production and metabolism is abnormal in women with pre-eclampsia and HELLP syndrome, perhaps contributing to the immunologic alterations characteristic of these disorders.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8887125     DOI: 10.1016/0165-0378(96)00976-x

Source DB:  PubMed          Journal:  J Reprod Immunol        ISSN: 0165-0378            Impact factor:   4.054


  7 in total

1.  Monocytes are primed to produce the Th1 type cytokine IL-12 in normal human pregnancy: an intracellular flow cytometric analysis of peripheral blood mononuclear cells.

Authors:  G P Sacks; C W G Redman; I L Sargent
Journal:  Clin Exp Immunol       Date:  2003-03       Impact factor: 4.330

2.  Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methods.

Authors:  Daniel B DiGiulio; Mariateresa Gervasi; Roberto Romero; Shali Mazaki-Tovi; Edi Vaisbuch; Juan Pedro Kusanovic; Kimberley S Seok; Ricardo Gómez; Pooja Mittal; Francesca Gotsch; Tinnakorn Chaiworapongsa; Enrique Oyarzún; Chong Jai Kim; David A Relman
Journal:  J Perinat Med       Date:  2010-09       Impact factor: 1.901

3.  Expression of Epstein-Barr virus-induced gene 3, an interleukin-12 p40-related molecule, throughout human pregnancy: involvement of syncytiotrophoblasts and extravillous trophoblasts.

Authors:  O Devergne; A Coulomb-L'Herminé; F Capel; M Moussa; F Capron
Journal:  Am J Pathol       Date:  2001-11       Impact factor: 4.307

4.  Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia.

Authors:  S Saito; M Sakai; Y Sasaki; K Tanebe; H Tsuda; T Michimata
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

5.  Myeloid and lymphoid dendritic cells in normal pregnancy and pre-eclampsia.

Authors:  D Darmochwal-Kolarz; J Rolinski; J Tabarkiewicz; B Leszczynska-Gorzelak; J Buczkowski; K Wojas; J Oleszczuk
Journal:  Clin Exp Immunol       Date:  2003-05       Impact factor: 4.330

6.  CXCL10/IP-10: a missing link between inflammation and anti-angiogenesis in preeclampsia?

Authors:  Francesca Gotsch; Roberto Romero; Lara Friel; Juan Pedro Kusanovic; Jimmy Espinoza; Offer Erez; Nandor Gabor Than; Pooja Mittal; Samuel Edwin; Bo Hyun Yoon; Chong Jai Kim; Shali Mazaki-Tovi; Tinnakorn Chaiworapongsa; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2007-11

7.  Serum levels of pro- and anti-inflammatory cytokines in non-pregnant women, during pregnancy, labour and abortion.

Authors:  S Vassiliadis; A Ranella; L Papadimitriou; A Makrygiannakis; I Athanassakis
Journal:  Mediators Inflamm       Date:  1998       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.